Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation - PubMed (original) (raw)
Review
Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation
J M Morales et al. Nephrol Dial Transplant. 2001.
Abstract
Cyclosporin and tacrolimus have improved survival figures in organ transplantation. However, both drugs are potentially nephrotoxic. The immunosuppressive and nephrotoxic effects of both drugs appear to depend on the inhibition of calcineurin. Cyclosporin and tacrolimus cause acute (functional changes) and chronic nephrotoxicity (structural lesions in the kidney). These last important lesions include arteriolar hyalinosis, stripped interstitial fibrosis and tubular atrophy. It is possible that repeated episodes of renal ischaemia contribute to the development of chronic nephrotoxicity and then chronic allograft nephropathy. Cyclosporin and tacrolimus also induce arterial hypertension. Therefore, the beneficial effects of immunosuppression have been limited due to nephrotoxicity and arterial hypertension. Rapamycin, a novel immunosuppressive agent, that does not inhibit calcineurin, provides immunosuppression without nephrotoxicity. In fact, in the trials performed in Europe, sirolimus-treated immunosuppression patients exhibited a much better renal function than cyclosporin-treated patients. However, sirolimus can potentiate the nephrotoxic effect of cyclosporin. Therefore, when cyclosporin and sirolimus are used in combination, a reduction of the cyclosporin dose is desirable.
Similar articles
- Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation.
Morales JM. Morales JM. Kidney Int Suppl. 2002 Dec;(82):S81-7. doi: 10.1046/j.1523-1755.62.s82.16.x. Kidney Int Suppl. 2002. PMID: 12410861 Review. - Calcineurin inhibitors in renal transplantation: what is the best option?
Tanabe K. Tanabe K. Drugs. 2003;63(15):1535-48. doi: 10.2165/00003495-200363150-00002. Drugs. 2003. PMID: 12887261 Review. - A case of tacrolimus nephrotoxicity appearing in a second renal transplantation patient.
Oka K, Moriyama T, Imai E, Kyo M, Toki K, Tanaka T, Hori M, Kokado Y, Okuyama A, Takahara S. Oka K, et al. Clin Transplant. 2001;15 Suppl 5:30-4. doi: 10.1034/j.1399-0012.2001.0150s5030.x. Clin Transplant. 2001. PMID: 11791792 - A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar?
Morozumi K, Sugito K, Oda A, Takeuchi O, Fukuda M, Usami T, Oikawa T, Fujinami T, Koyama K, Takeda A, Yoshida A, Haba T, Tominaga Y, Uchida K, Yokoyama I, Takagi H. Morozumi K, et al. Transplant Proc. 1996 Apr;28(2):1076-8. Transplant Proc. 1996. PMID: 8623232 No abstract available. - Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM, Kobashigawa J, Klintmalm G. Flechner SM, et al. Clin Transplant. 2008 Jan-Feb;22(1):1-15. doi: 10.1111/j.1399-0012.2007.00739.x. Clin Transplant. 2008. PMID: 18217899 Review.
Cited by
- Correlations between serum kidney injury molecule-1, cystatin C and immunosuppressants: A cross-sectional study of renal transplant patients in Bahrain.
Sridharan K, Shah S, Hammad MA, Mohammed FA, Veeramuthu S, Taher MA, Hammad MM, Jawad L, Farid E. Sridharan K, et al. J Biomed Res. 2024 Mar 26;38(3):269-277. doi: 10.7555/JBR.37.20220211. J Biomed Res. 2024. PMID: 38528676 Free PMC article. - Formulation strategies for drug delivery of tacrolimus: An overview.
Patel P, Patel H, Panchal S, Mehta T. Patel P, et al. Int J Pharm Investig. 2012 Oct;2(4):169-75. doi: 10.4103/2230-973X.106981. Int J Pharm Investig. 2012. PMID: 23580932 Free PMC article. - Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience.
Alarrayed SM, El-Agroudy AE, Alarrayed AS, Al Ghareeb SM, Garadah TS, El-Sharqawi SY, Al-Aradi AH, Dandi BG, Abdulla S. Alarrayed SM, et al. Clin Exp Nephrol. 2010 Jun;14(3):248-55. doi: 10.1007/s10157-010-0269-0. Epub 2010 Mar 16. Clin Exp Nephrol. 2010. PMID: 20232105 - Secondary hypertension: interfering substances.
Grossman E, Messerli FH. Grossman E, et al. J Clin Hypertens (Greenwich). 2008 Jul;10(7):556-66. doi: 10.1111/j.1751-7176.2008.07758.x. J Clin Hypertens (Greenwich). 2008. PMID: 18607141 Free PMC article. Review. - Comprehensive review of cardiovascular toxicity of drugs and related agents.
Mladěnka P, Applová L, Patočka J, Costa VM, Remiao F, Pourová J, Mladěnka A, Karlíčková J, Jahodář L, Vopršalová M, Varner KJ, Štěrba M; TOX-OER and CARDIOTOX Hradec Králové Researchers and Collaborators. Mladěnka P, et al. Med Res Rev. 2018 Jul;38(4):1332-1403. doi: 10.1002/med.21476. Epub 2018 Jan 5. Med Res Rev. 2018. PMID: 29315692 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical